Literature DB >> 33225838

Physicochemical characteristics and in vitro permeation of loratadine solid lipid nanoparticles for transdermal delivery.

Omar Sarheed1, Douha Shouqair1, Kvrns Ramesh1, Muhammad Amin2, Joshua Boateng2, Markus Drechsler3.   

Abstract

Aim: To prepare loratadine-loaded solid lipid nanoparticles (SLNs) using a modified two-step ultrasound-assisted phase inversion temperature (PIT) process. Results/methodology: Loratadine was dissolved in beeswax and Tween 80 was dissolved in water. The two phases were mixed together to prepare a water-in-oil emulsion preconcentrate (w/o) at a PIT of 85°C, followed by gradual water addition at 25°C to trigger nanoparticles formation (o/w). Kinetic stability was investigated. No change in the size was observed within 6 months. Fourier-transform infrared spectroscopy demonstrated stability of the emulsions via molecular structure of water at the interface of the o/w nanoemulsions. SLNs enhanced the in vitro skin permeation of loratadine.
Conclusion: Stable SLNs were successfully prepared by ultrasound-assisted PIT.

Entities:  

Keywords:  Franz diffusion cell; permeation; phase inversion temperature; pig skin; solid lipid nanoparticles; synthetic membrane; transdermal

Year:  2020        PMID: 33225838     DOI: 10.4155/tde-2020-0075

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  2 in total

1.  Fabrication of Alginate-Based O/W Nanoemulsions for Transdermal Drug Delivery of Lidocaine: Influence of the Oil Phase and Surfactant.

Authors:  Omar Sarheed; Manar Dibi; Kanteti V R N S Ramesh; Markus Drechsler
Journal:  Molecules       Date:  2021-04-27       Impact factor: 4.411

2.  Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation.

Authors:  Rehab Abdelmonem; Inas Essam Ibrahim Al-Samadi; Rasha M El Nashar; Bhaskara R Jasti; Mohamed A El-Nabarawi
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.